Capital investment focused on the collagen materials business
First written in FY2016. 13 of 14 entries say "Advanced", first in FY2017. Latest entry: 2026-05-14.
The whole theme swung hardest in 2020: 2 of 14 companies on the "Worse" side.
10 other companies' latest entry also says "Advanced".
- FY2026-H1AdvancedAnnual report
「Cash used in investing activities was ¥3,130 million, compared with ¥1,570 million used in the same period of the previous year. The main factors were ¥2,303 million in payments for deposits into time deposits and ¥831 million in payments for the acquisition of property, plant and equipment.」
During the interim consolidated accounting period, ¥831 million was spent on the acquisition of property, plant and equipment, and capital investment in production and supply infrastructure and other areas is continuing. - FY2025AdvancedAnnual report
「The group made ¥1,838 million in capital investments to maintain and optimize its globally stable production and supply structure.」
To maintain and optimize a stable production and supply structure, the company made ¥1,838 million in capital investments during the current fiscal year, including ¥1,219 million in domestic manufacturing and environmental protection equipment and ¥619 million in overseas plants. - FY2024-Q2AdvancedAnnual report
「Cash used in investing activities was ¥1,578 million, compared with ¥1,678 million used in the same period of the previous year. The main factor was ¥1,541 million in payments for the acquisition of property, plant and equipment.」
During the cumulative second-quarter period, ¥1,541 million was spent on the acquisition of property, plant and equipment, and capital investment in the production and research and development infrastructure and other areas continues. - FY2023-Q3AdvancedAnnual report
「In December 2022, the Company completed Mirai-kan, a new research, development and manufacturing building, consolidating the research and development and production functions for biomedical products and the research and development functions of all business divisions to create products leading to new businesses.」
Investment in the research and development and production infrastructure reached the specific milestone of completing construction of the new research and manufacturing building, Mirai-kan. - FY2023-Q2AdvancedAnnual report
「Cash used in investing activities was ¥1,678 million, compared with ¥522 million used in the same period of the previous year. The main factor was ¥1,647 million in payments for the acquisition of property, plant and equipment.」
During the cumulative second-quarter period, ¥1,647 million was spent on the acquisition of property, plant and equipment, and capital investment in the production and research and development infrastructure and other areas continues. - FY2022-Q2AdvancedAnnual report
「In September 2021, construction began on Mirai-kan, a new research building intended to strengthen the business base by consolidating biomedical product production and the research and development functions of all business divisions and creating products leading to new businesses. Completion was scheduled for autumn 2022.」
Investment in the production and research and development infrastructure has progressed to the stage of commencing construction of the new research building, Mirai-kan. - FY2021AdvancedAnnual report
「The group made ¥1,359 million in capital investments to optimize its global production and supply structure, further pursue selectivity and concentration, create high-value-added products and services, and transform its corporate structure to generate higher profitability.」
The company made ¥1,359 million in capital investments during the current fiscal year and has progressed to the investment phase for new development and increased production of medical collagen products and the construction of a new research building, in addition to maintaining production and improving quality in Japan and overseas. - FY2021-Q2AdvancedAnnual report
「Cash used in investing activities was ¥607 million, compared with ¥539 million used in the same period of the previous year. The main factor was ¥605 million in payments for the acquisition of property, plant and equipment.」
During the cumulative second-quarter period, ¥605 million was spent on the acquisition of property, plant and equipment, and capital investment continued. - FY2018AdvancedAnnual report
「Based on business strategies including the development of high-value-added products, optimized production and sales, and improved productivity, the group made ¥1,269 million in capital investments, primarily in the collagen materials business.」
The company made ¥1,269 million in capital investments during the current fiscal year and plans to invest ¥1,700 million over the following year. Investment continues in domestic equipment upgrades, environmental improvements in India and facilities in North America. - FY2018-Q2AdvancedAnnual report
「Cash used in investing activities was ¥857 million, compared with ¥1,668 million used in the same period of the previous year. The main factor was ¥845 million in payments for the acquisition of property, plant and equipment.」
During the cumulative second-quarter period, ¥845 million was spent on the acquisition of property, plant and equipment for capital investment. The details of individual facilities are not provided here. - FY2017AdvancedAnnual report
「Based on business strategies including the development of high-value-added products, optimized production and sales of gelatin and collagen peptide products, and improved collagen casing productivity, the group made ¥2,060 million in capital investments, primarily in the collagen materials business.」
Against the previous plan of ¥2,670 million, ¥2,060 million was invested during the current fiscal year. Specific investments progressed at the North American casing plant, the Indian gelatin plant and domestic plants. The plan for the one-year period following the next consolidated fiscal year is ¥1,900 million. - FY2016First statedAnnual report
「The capital investment plan for the one-year period following the end of the current consolidated fiscal year, including new construction and expansion, totals ¥2,670 million. The breakdown by segment is as follows.」
The plan includes ¥2,510 million for the collagen materials business, ¥50 million for the formula solutions business and ¥110 million for corporate-wide activities, to be used to improve quality and productivity, including casing production productivity.